Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
about
Big data for bipolar disorder.Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropePro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropeTime-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug EventsAssessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Differences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations.Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachAntipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes: an investigation of the regulator in JapanThe Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular AntipsychoticsThe Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis.Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Cardiovascular safety of antipsychotics: a clinical overview.Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death.Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation.Generic atypical antipsychotic drugs in Belgium: their influence and implications.Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies.Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice.A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system.A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System.An evaluation of the Manufacturer And User Facility Device Experience database that inspired the United States Food and Drug Administration's Reclassification of transvaginal mesh.QT and QTc in Male Patients with Psychotic Disorders Treated with Atypical Neuroleptics.Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest
P2860
Q26749257-74F4AA05-BFAF-43E0-B28F-A8E7BCFCDA6EQ28535299-FD497B12-DB3A-427B-AC99-4EC912948101Q28544621-02B69D48-A234-45AE-8976-868507819FE7Q28554594-A1842F7B-2717-4771-B91C-57532F573F17Q30852962-EB4C05A9-F2BD-4D7A-A7EE-63137E80E6BFQ33617259-CD3274F7-53B7-48B2-8F7E-7ABFB769CD3BQ33816182-45B8334E-5570-45A5-9113-CD3E05A329DEQ34464293-F3425A4C-751D-4B4D-887E-7CE5599E4428Q35135720-D73C015D-C2CB-43A6-BEE3-8506A3980E6AQ35754726-075D7890-59B1-4215-B3B8-2FE285D8EFD6Q36152855-92454101-B6B9-48ED-A034-5CE7FBB86472Q36460550-466FA118-EC61-49BC-B6EA-392600E39223Q37212537-6F44D8BA-D86D-4A7A-8D18-0C359712528AQ37683523-85EEBA5B-40C2-453A-9B76-05DF48E9A069Q38175457-59F24534-F5D6-41DB-84B4-59A1A64E890BQ38185057-65A65699-C986-45D9-A8FF-D39A147B74DDQ38296631-D05DE8B6-76DF-4E49-88F1-9125CDA30DD7Q38408656-221C7BF1-C457-4568-BF6B-49E70516BC53Q38501976-FC673840-EC87-42A7-B5EA-5B101F7DC5B0Q38757870-AC14646B-9FD0-48CA-B04A-52E1A416A690Q38919237-F525B607-B0AA-48FC-BBE3-E84F4C80BB38Q41581299-E109D8FD-D7C1-4C6C-BEB9-5C3741E6DFCBQ43897779-73CD0FB7-A90A-44FC-B826-6E9FC4317AB6Q45809881-DD9B018D-7FB5-46B1-8C38-DC9DCAAFC15EQ48197901-A52CAC11-EAF5-4BCA-8217-FB07EC3AC7E1Q48302148-1837C5CF-89CC-40D3-979D-D900DAC8934EQ52604170-1A8456BB-6D58-4180-849B-CC732F57BBDFQ52624670-A19F492E-9DD3-446A-ABB3-4764848D238BQ52665543-8E41352E-F737-47A0-91D9-D2B6E80BB226Q55437891-1F5BE93A-2F2A-4353-9D8A-704566FCF31CQ57260313-540995C2-38CE-4438-AD79-7D5D4A9B03F0
P2860
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Antipsychotics and torsadogeni ...... ent Reporting System database.
@ast
Antipsychotics and torsadogeni ...... ent Reporting System database.
@en
Antipsychotics and torsadogeni ...... ent Reporting System database.
@nl
type
label
Antipsychotics and torsadogeni ...... ent Reporting System database.
@ast
Antipsychotics and torsadogeni ...... ent Reporting System database.
@en
Antipsychotics and torsadogeni ...... ent Reporting System database.
@nl
prefLabel
Antipsychotics and torsadogeni ...... ent Reporting System database.
@ast
Antipsychotics and torsadogeni ...... ent Reporting System database.
@en
Antipsychotics and torsadogeni ...... ent Reporting System database.
@nl
P2093
P2860
P50
P1433
P1476
Antipsychotics and torsadogeni ...... vent Reporting System database
@en
P2093
Ariola Koci
Miriam Sturkenboom
Ugo Moretti
P2860
P2888
P304
P356
10.1007/S40264-013-0032-Z
P577
2013-06-01T00:00:00Z
P5875
P6179
1016062014